Stability testing - including accelerated aging (often per ASTM F1980) and real-time aging - generates data to support shelf-life claims, packaging integrity, and continued sterility for terminally sterilized devices. Accelerated aging uses higher temperatures and the Arrhenius rule (often Q10 = 2) to estimate shelf life quickly, but real-time aging must follow to confirm the claim. Tests check seal strength, package integrity and device function after aging. ISO 11607 and FDA expectations require that shelf-life claims on the label are supported by this data.

Why it matters

Real-time data must eventually replace accelerated estimates. Stability data supports labeling claims and is reviewed during 510(k)/PMA submissions and Notified Body audits.

Common pitfalls

•Failing to establish a documented stability testing plan before device launch can lead to regulatory non-compliance.
•Extrapolating accelerated aging data too far beyond validated real-time data without sufficient justification is a common pitfall.
•Not considering the impact of multiple sterilization cycles or reprocessing on device stability for reusable devices can lead to safety issues.
•Inadequate sample sizes for stability studies may result in statistically unreliable data.
•Changes in materials or manufacturing processes without re-evaluating stability can invalidate existing shelf-life claims.

Sources

ASTM F1980 · ASTM
ISO 13485 Standard Page · ISO
GHTF/IMDRF Process Validation Guidance · IMDRF/GHTF

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.